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Drug Screening for Discovery of 
Broad-spectrum Agents for Soil-
transmitted nematodes
Mostafa A. elfawal1, Sergey n. Savinov2 & Raffi V. Aroian1
Soil-transmitted nematodes (Stns), namely hookworms, whipworms, and ascarids, are extremely 
common parasites, infecting 1–2 billion of the poorest people worldwide. Two benzimidazoles, 
albendazole and mebendazole, are currently used in STN mass drug administration, with many 
instances of low/reduced activity reported. new drugs against Stns are urgently needed. We tested 
various models for STN drug screening with the aim of identifying the most effective tactics for 
the discovery of potent, safe and broad-spectrum agents. We screened a 1280-compound library 
of approved drugs to completion against late larval/adult stages and egg/larval stages of both the 
human hookworm parasite Ancylostoma ceylanicum and the free-living nematode Caenorhabditis 
elegans, which is often used as a surrogate for Stns in screens. the quality of positives was further 
evaluated based on cheminformatics/data mining analyses and activity against evolutionarily distant 
Trichuris muris whipworm adults. From these data, two pairs of positives, sulconazole/econazole and 
pararosaniline/cetylpyridinium, predicted to target nematode CYP-450 and HSP-90 respectively, were 
prioritized for in vivo evaluation against A. ceylanicum infections in hamsters. one of these positives, 
pararosaniline, showed a significant impact on hookworm fecundity in vivo. taken together, our results 
suggest that anthelmintic screening with A. ceylanicum larval stages is superior to C. elegans based on 
both reduced false negative rate and superior overall quality of actives. Our results also highlight two 
potentially important targets for the discovery of broad-spectrum human STN drugs.
Soil transmitted nematodes (STNs) of humans- the giant roundworm Ascaris lumbricoides, whipworm Trichuris 
trichiura, and three hookworm species Necator americanus, Ancylostoma duodenale, and Ancylostoma ceylanicum 
–are intestinal parasites responsible for much of the morbidity associated with the neglected tropical diseases that 
sustain the cycle of poverty1,2. An estimated 438.9, 819, and 646.6 million people are infected with hookworms, 
giant roundworms, and whipworms, respectively, and, together, these parasites are responsible for at least 4.98 
million years lived with disability YLDs3. Morbidity associated with STN infections include growth stunting, 
malnutrition, anemia, and cognitive impairment1,4,5. Of all these parasites, hookworms outrank the other STNs 
in terms of morbidity and are associated with significant contributions to anemia in children, pregnant women 
and adults5,6. A. ceylanicum is a zoonotic hookworm species that infects humans, cats, and dogs and a prevalent 
hookworm parasite in humans in Southeast Asia7–11.
To combat STNs, the World Health Organization (WHO) has recommended a long-term plan to improve 
sanitation and health education to limit infection, as well as routine Mass Drug Administration (MDA) cam-
paigns targeting pre-school and school-aged children to eliminate morbidity12. Currently two benzimidazole 
drugs, namely, albendazole and mebendazole, originally developed for farm animal use, are adopted by the WHO 
in MDA against human parasites. Unfortunately, drug resistance against benzimidazoles and other anthelmintics 
is well established in veterinary parasites13–17. Benzimidazole resistance alleles have been found in human STNs 
and their increased frequency following anthelmintic treatment has been observed18–20. There are also multiple 
reports indicating low efficacy of albendazole against STNs21–25, and good single-drug efficacy against whipworms 
is lacking26–28. New screens for potent anthelmintic drugs with broad specificity and new mechanisms of action 
are thus urgently needed. Phenotypic screening, also called “whole organism screening,” remains an essential and 
productive approach for drug discovery, including for anthelmintics29–31. Target-based approaches, in contrast to 
phenotypic screening, require significant understanding of parasite biology (e.g., is the target essential? accessible 
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to a given drug?), which is limiting for STNs. In phenotypic screening, identification of positives does not require 
the same amount of knowledge about the parasite but rather relies on the ability to test many molecules covering 
large area of chemical space.
Phenotypic drug screens against STNs have lagged behind that of many other diseases because of the difficulty 
in getting large quantities of relevant stages of STNs for screening and the relative dearth of studies testing and 
validating an appropriate screening system. Screens to date include using adult parasites in vitro32,33, eggs hatch 
assay22,34, larval-staged parasites33–35, infective third stage parasitic larvae (L3i)36,37, and the free-living nematode 
Caenorhabditis elegans as a surrogate33,38–42. Despite these studies, little groundwork has been done to determine 
the comparative validity and usefulness of such screens towards finding an anthelmintic against STNs that is effi-
cacious in vivo in laboratory models or that would be useful in human therapy. In addition, there have been little 
studies done regarding optimization of even a moderate throughput pipeline for gastrointestinal nematode drug 
discovery while also focusing on or addressing the false positive and false negatives of the screening models used 
(e.g., the drug screens with adults above investigated at most 400 compounds).
To address these limitations while also performing a screen for effective anthelmintics, we screened to comple-
tion a 1,280-compound approved drug library (FDA, EMA and other agencies) against A. ceylanicum hookworm 
adults and egg/larval stages in vitro and against C. elegans fourth larvae (L4)/adult and egg/larval stages. Half of 
the FDA library (640 drugs) was also tested against regular and exsheathed A. ceylanicum L3i. Hookworm adult 
positives were further subjected to screening against whipworm adults, as well as cheminformatics and data min-
ing analyses for down selection and prioritization. These analyses resulted in four candidate drugs that were taken 
forward for in vivo testing against hookworms in infected hamsters. Based on these data, we (i) propose a novel 
screening pipeline for STN drug discovery, (ii) identify an antiparasitic with heretofore unknown efficacy against 
hookworms based on parasite in vivo fecundity, and (iii) report on the potential identification of two putative 
targets for broad-spectrum STN therapy.
Results
Screening of an approved drug library against hookworm adults. Since adult parasites are the pri-
mary in vivo therapeutic target for anti-STN drugs and since large-scale drug screening cannot be reasonably 
carried out in vivo using infected rodents, we chose adult parasite in vitro screening as our standard against which 
all other screens would be compared. Since the human-parasitic hookworm A. ceylanicum can be maintained in 
immunocompetent hamsters, it is a relevant parasite to test as an actual human parasite in the laboratory.
To establish which compounds in the library have activity against adult hookworms, all 1280 compounds 
were screened against A. ceylanicum adults and scored for impacts on motility and morphology (Fig. 1A,B). 
Out of the1280 drugs, 39 were found to be effective against adult A. ceylanicum parasites with ~3% hit rate 
(Table S1). Those 39 drugs span a diverse range of established biological activities, including analgesic, antibac-
terial, antifungal, antipsychotic, and antianginal. The screen was validated by selecting two of the 96-well plates 
(160 compounds)–one with the highest number of actives (6) and one with no actives in the initial screening, and 
rescreening them with adult A. ceylanicum parasites. There was perfect correspondence for compounds that were 
considered active and inactive in both screens.
Screening of library using free-living C. elegans and free-living stages of A. ceylanicum. In 
order to test for convergence between various models with our adult hookworm standard, we next screened the 
library to completion using two C. elegans stages and the free-living egg-to-larval (E2L) stages of A. ceylanicum 
hookworms. By screening the entire library against these potential surrogates, we can determine both the false 
positive rate (actives that kill or intoxicate the surrogate but not the adult hookworm standard) and the false neg-
ative rate (actives that kill or intoxicate the adult hookworm standard but not the surrogate). The false negative 
rate has generally been poorly characterized in anthelmintic discovery studies but is important since it reveals if 
excellent actives might be missed by using an inadequate surrogate. We screened the entire library using different 
stages of C. elegans since different stages have been preferred in previous studies.
For screening against the free-living stage of A. ceylanicum hookworms, eggs were isolated from 
hookworm-infected hamsters, cleaned up, and dispensed into 96 well-plates with an Escherichia coli food source. 
Over the course of 7 days, on average 85% of these eggs hatch and the resulting larvae grow and develop to 
the L3i stage in the absence of any drug (at which point they require a host to continue normal development). 
This 96-well plate assay, which we call egg-to-larva (E2L), recreates the soil/environmental stage of hookworms. 
Examples of screening with this E2L assay are shown in Fig. 2A–C. We set up a parallel egg-to-adult (E2A) assay 
with C. elegans, plating eggs in a 96-well format and allowing them to develop for 3 days until the adult stage was 
reached (Fig. 2D–F). As a parallel C. elegans assay for hookworm adults, we distributed late-staged C. elegans 
larvae (fourth stage or L4) in a 96-well format that, over the course of four days, develop into adults with signif-
icant brood sizes (Fig. 2G–I). The library was screened to its entirety with hookworm E2L, C. elegans E2A, and 
C. elegans L4s. The DMSO concentration was kept to levels that did not affect control (no drug) wells. Each was 
screened at 30 µM, as was done for adult hookworms. Since earlier stages tend to be more sensitive to drug than 
later stages, we also screened hookworm E2L and C. elegans E2A at 10 µM in order to compare results at multiple 
doses.
The number of total actives and inactives found in all these screens and their overlap with the adult hookworm 
standard actives are indicated Table 1 and graphically in Fig. 3. The success rate (“true positive rate” or TPR) of 
each model was calculated as the number of actives overlapping with adult A. ceylanicum (Fig. 3). In order from 
the most successful to least successful we found: A. ceylanicum E2L (30 µM) 69% TPR, A. ceylanicum E2L (10 µM) 
46% TPR, C. elegans L4 (30 µM) 36% TPR, C. elegans E2A (30 µM) 28% TPR, and C. elegans E2A (10 µM) 18% 
TPR. Which of the adult hookworm standard 39 positives overlapped with those from other screening methods 
is shown in Table S1.
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Screening the library with L3i and xL3i hookworm parasites. Infectious staged larvae (L3i) have also 
been proposed as a screening method36,37,43. Getting large quantities of these is a relatively straightforward task 
and, for some veterinary parasites, like Haemonchus contortus, extremely large quantities can be cultured from 
a single infected animal (e.g., sheep) for extended periods of time. However, this stage of parasitic nematodes 
are covered in a protective sheath and metabolically dormant, awaiting a host to exsheath and become active 
again44,45. As such, it has been proposed that exsheathed larvae (xL3) may be a better model for anti-nematode 
drug screening33,36. To test the utility of L3i or induced xL3i for drug screening, 640 compounds from the library 
were also screened against these stages. As indicated in Table 1, we found that these stages, like C. elegans, tended 
to give more false negatives than hookworm E2L, although the number of false positives was very low.
Data mining and chemoinformatic characterization of hits. We also set out to determine the quality 
of the hits that each screening system produced. The quality of the hits were established in two ways. First, we used 
data mining and cheminformatics to characterize the 39 actives against adult hookworm parasites (Table S2). The 
39 actives were split into two groups—those that were active against parasitic nematode, A. ceylanicum, but not 
the free-living nematode, C. elegans (Parasite-specific or PS) and those that were active against both the para-
sitic and free-living nematodes (Nematode-General or NG). The performance of PS and NG sets in the anthel-
mintic screen was compared to the performance of the same compounds in cytotoxicity assays deposited into the 
PubChem database. The two PubChem assays that screened the largest number of these compounds (33 and 30, 
respectively) are those against chicken DT40 (AID743012) and human HEK293 (AID1224886) cell lines. Of the 
compounds that were evaluated in these assays, 54% (7/13) and 40% (4/10) of NG actives had IC50 values at a 
submicromolar level in AID743012 and AID1224886, respectively, whereas the values for the PS hits were 15% 
(3/20) and 0% (0/19), respectively. At the same time, the percentages of moderately cytotoxic and non-cytotoxic 
compounds (IC50 ≥ 10 µM) were 23% and 36% for NG and 50% and 63% for PS. Although the sample size is 
admittedly limited, it is, nonetheless, notable that the smaller subset of PS-adult hits discovered via E2L screen 
also displays this reduced cytotoxicity trend. Thus, the IC50 values in the submicromolar range were shown by 
2 (out of 10) and 0 (out of 10) such compounds in AID743012 and AID1224886 cytotoxic screens, respectively.
Figure 1. Example of screening with adult A. ceylanicum hookworms in 96 well plate. (A) Three adult 
hookworms in DMSO control well showing healthy parasites with normal gut morphology; (B) Three adult 
hookworms in well with active compound; animals are dead or shrunken, showing abnormal gut morphology. 
Scale bar here and elsewhere = 1 mm.
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In vitro whipworm screening. As a second independent measure of positives’ quality and for further pri-
oritization of compounds, we performed a secondary in vitro screen of the adult hookworm actives against the 
adult stage of a distantly related intestinal nematode parasite, whipworm. Drugs that target multiple STNs are of 
much higher priority than drugs that target only individual parasites—e.g., due to the economics of drug devel-
opment and the practicality of MDA in resource poor populations. T. muris whipworm adults were screened in 
Figure 2. Phenotypic examples of actives in A. ceylanicum E2L screen (A–C), C. elegans E2A screen (D–F), 
C. elegans L4-Adult screen (G–I) and A. ceylanicum xL3i screen (J,K). (A,D,G,J) Showing DMSO control with 
healthy nematodes, including normal morphology (all), development (A,D), and fecundity (G). Motility was 
also normal in all wells. (B,C,E,F,H,I,K) Examples of actives with arrested or stunted growth (B,C,E,F), dead C. 

















Total actives 39 108 34 29 7 of 640 9 of 640 58 15
Overlapping with HW adults . 27 14 10 7 of 20 7 of 20 18 7
Non-HW adult (false positives) . 81 20 19 0 2 41 8
Missed HW adult (false negatives) . 12 25 28 13 of 20 13 of 20 21 32
Table 1. The total number of actives from each model tested, the number of overlapping hits with the 
hookworm (HW) A. ceylanicum adult standard actives, and the number of false positives and false negatives.
Figure 3. Actives Venn diagram. Shown schematically are the number of actives discovered using each of A. 
ceylanicum E2L, C. elegans L4 and C. elegans E2A overlapping with the 39 A. ceylanicum adult standard actives. 
Areas are representative of actual overlap rations. A. ceylanicum E2L showed the highest number of overlapping 
actives (27 of 39) with A. ceylanicum adults standard actives and the lowest percentage of the false negatives 
compared to C. elegans L4 and E2A.
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vitro against as many of the adult hookworm standard positives as we could readily get access to from commercial 
suppliers (32 out of 39). Out of those 32 drugs, 19 were found to be effective against whipworms at a 100 µM dose 
(Fig. 4; Tables 2, S1). Moreover, the hookworm E2L screening was again superior to any of the C. elegаns screens 
in recalling compounds with broad-spectrum activity against adult nematode parasites. Hookworm E2L was 
able to detect 16 of the 19 actives against T. muris, compared to only eight and six detected using C. elegans L4 
and E2A, respectively (Table 2). All of the whipworm adult positives captured by C. elegans were also captured by 
hookworm E2L.
The broad-spectrum STN adult actives recalled by hookworm E2L, but not by the C. elegans screens, also tend 
to display lower cytotoxicity profile (Table S3), with only one out of seven such hits (positive on hookworm E2L 
but negative on C. elegans) exhibiting submicromolar activity in the PubChem cytotoxicity assays discussed above 
(AID743012 or AID1224886). On the other hand four out of nine broad-spectrum STN adult actives recalled 
by the C. elegans L4 assay show cytotoxicities in the submicromolar range in the same assays. In addition, seven 
out of nine C. elegans-recalled actives have legacy murine oral LD50 values in the high toxicity range (<300 mg/
kg), whereas only two out of seven broad spectrum actives recalled only by the hookworm E2L assay were in this 
range, highlighting the potential value of parasitic E2L as a primary screening system over C. elegans.
In vivo screening against A. ceylanicum. Of the 19 broad-spectrum STN adult actives, four were prior-
itized and selected for in vivo testing. These four were selected on the basis of their putative and inferred targets 
Figure 4. Adult T. muris whipworm example screening in 24 well plate. (A) DMSO healthy and motile 
whipworms, with an abundance of released eggs; (B) Dead whipworms in well with active compound.








Total Actives 19 21 12 6
Whipworms overlapping actives . 16 8 6
Whipworms missed actives . 3 11 13
Table 2. The total number of T. muris actives out of 32 drugs active against A. ceylanicum adults . Each 
model tested was reevaluated for its ability to detect those drugs that affect whipworms adults. Out of the 32 
hookworm standard actives, 19 showed activity against whipworms. Among all model tested E2L showed the 
highest number of overlapping actives (16 out of 19) with adult whipworms, compared to 8 and 6 in C. elegans 
L4 and E2A.
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in parasites, the importance of these targets to parasitism, and in the safety profile of these drugs. The four drugs 
selected were econazole nitrate, sulconazole nitrate, pararosaniline hydrochloride, and cetylpyridinium chlo-
ride. In prior repurposing screens, the first two drugs were found to have potent inhibitory activities against a 
cytochrome P450 (CYP-450) in a parasitic flatworm46 whereas the latter two were found to be effective against an 
amoeboid parasite by targeting its Heat Shock Protein 90 (HSP-90)47. Both of these are believed to play critical 
roles in both parasite viability and the process of parasitism48–50. We screened these four drugs directly in ham-
sters infected with A. ceylanicum. Among all four treatments, one and only compound, pararosaniline, showed 
significant reduction in fecal egg counts (Fig. 5A; no significant reduction in worm burdens seen; Fig. S1A). 
This result was independently repeated and pararosaniline was re-tested against A. ceylanicum-infected hamsters 
(Figs 5B, S1B).
Discussion
In this work we have compared the efficiency of different screening models for STN drug discovery. We con-
sidered adult in vitro screening as the best standard, since it is the life stage responsible for disease burden in 
vertebrate hosts, then evaluated each model for its ability to detect hits that also affect adults (true positive rates 
or TPRs), as well as false positive and false negative rates. Considering the dose of 30 µM, which was used for all 
stages screened, hookworm E2L screen was associated with the highest TPR with the adult hookworm actives 
(27/39) and the lowest number of the corresponding false negatives (12). On the other hand, C. elegans displayed 
a far worse TPR (11/39 for E2A and 14/39 for L4) and a significantly higher number of false negatives (28 for E2A, 
25 for L4). Based on our data, C. elegans will therefore miss at more than twice as many adulticidal hits as parasitic 
larvae. L3i and xL3i were also inferior to hookworm E2L with regards to TPR. With regards to known anthel-
mintics, we found 15 in the library with known activity against one or more nematodes. Of these, hookworm E2L 
correctly identified 13/15. The only two it did not find were morantel and oxantel, two compounds with narrow 
spectrum of activity that are known to not work well against hookworms36,51 (these were both missed by C. elegans 
as well), further validating the usefulness of hookworm E2L for drug screening.
Although hookworm E2L also resulted in a higher number of false positives, false positives in a primary screen 
of a multi-step screening campaign is less critical than the false negatives since the later represents a permanent 
dismissal of a potentially the best candidates and since a high number of false positives in a primary screen could 
be trimmed effectively by secondary screens (e.g., against parasite adults). Moreover, many compounds that we 
termed “false positives” were structurally similar to their “true positive” counterparts and, likely, just didn’t reach 
the established activity threshold. For example many other azoles structurally related to econazole and sulcana-
zole (miconazole and oxyconazole) were not as effective against hookworm adults, but were sufficiently active 
against the E2L system to be registered as hits. These “false positives” do then bring an added value of validating 
both the “true positive” hits and their putative targets. One caveat to our findings is that our conclusions are based 
upon screening of a library that contained 1280 compounds. The screening of this library to its entirety or near 
entirety against adult parasites, larval parasitic stages, and two C. elegans stages is unprecedented and provides a 
solid foundation for comparison.
Other analyses and data support these conclusions. First, parasite-specific positives show lower overall toxicity 
than positives that overlap between the parasites and C. elegans. Furthermore, hookworm larvae are much more 
likely to discover positives that have broader spectrum against STN adults (hookworms + whipworms) than C. 
elegans. Again, such positives are less likely to be generally toxic. Taken together, our results indicate that, whereas 
Figure 5. In vivo activity of down-selected library compounds against A. ceylanicum infections in hamsters. (A) 
Eggs per gram of feces (EPG) in hamsters given a single oral dose of 50 mg/kg of each of the four compounds 
compared to water control. Only pararosaniline showed significant reduction (46%) compared to control (all 
other comparisons relative to control did not reach significance); (B) EPGs in hamsters given a single oral dose 
of 100 mg/kg pararosaniline, showing significant reduction (30%) relative to control. Numbers above bars 
indicate P values. Long horizontal lines represent EPG means; short horizontal lines represent standard error.
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C. elegans is capable of detecting some anti-STN drugs, it is much more likely to miss the best candidates in terms 
of adult parasitic activity and lower toxicity. These findings were confirmed by in vivo screening of our prioritized 
candidates. Of the four candidates tested in vivo, the only one that showed significant impact against the para-
sites was picked up by hookworm E2L but was absent in all C. elegans screens (and hookworm L3i and xL3i). As 
expected for a non-optimized hit from a small library, pararosaniline is not as effective against hookworms as 
well-known fully developed anthelmintics that have been used clinically for decades, such as albendazole, pyran-
tel, and ivermectin, all of which have strong effects in vivo at 6 mg/kg in this model52.
Consistent with our findings, it has been noted that, although the use of C. elegans as a model for parasitic 
nematodes started 30 years ago with tens of millions of drugs having been screened against it, no single com-
pound discovered with C. elegans has yet reached the clinic31. Indeed, animal health pharmaceutical laboratories 
have been the source of all the anthelmintics in use now, including against human STNs. For example, three of 
the latest drugs in use against gastrointestinal nematodes, paraherquamide, emodepside, and monepantel, were 
found in screens against parasitic nematodes of veterinary importance, although little or no details of how these 
screens were carried out were given53–55. Interestingly, in our research on the initial discovery of deworming 
drugs used today35,53,54,56–59, five were discovered as anthelmintics screening in vivo against parasitic nematode 
infections in whole host-animals (ivermectin, paraherquamide, emodepside, levamisole, and pyrantel) and two 
were discovered using parasitic larval assays (benzimidazoles, monepantel), further validating the importance of 
parasite larvae as an effective screening tool, in this case for human STNs.
Our screening results also highlight two important putative targets for STN drug development, CYP-450 and 
HSP-90. C. elegans harbors a large repertoire of >60 cytochrome P-450 genes60, a phenomenon that is believed to 
enhance drugs biotransformation and elimination, perhaps contributing to C. elegans as a poor model for pheno-
typic anthelmintic screens. In contrast, parasitic nematodes harbor fewer CYP-450 enzymes. In fact, it was once 
believed that CYP-450 activity was generally absent in parasitic nematodes61. However, recent studies have shown 
that parasitic nematodes possess CYP-450 enzymes, albeit in limited quantity, and established their essential roles 
in the process of parasitism48. CYP450’s are heme-containing monooxygenases that play critical roles in xeno-
biotic biotransformations and in the metabolism of essential endobiotic compounds such as sterol, cholesterol 
and ergosterol62–64. The imidazole derivatives-econazole and sulconazole- were developed mainly as antifungal 
drugs inhibiting fungal CYP450’s, leading to a decreased production of ergosterol, the essential bioregulator of 
fungal cell membrane fluidity and integrity65–67. The CYP-450 inhibitors, econazole and sulconazole, were found 
to display antiparasitic activity against Schistosoma mansoni46, antitrypanosomal activity68 against Trypanosoma 
cruzi, and antibacterial activity against Mycobacterium tuberculosis69 and against the drug resistant Salmonella 
typhimurium70. The antiparasitic activity of imidazoles is believed to act through their inhibitory activity against 
CYP-450’s that was recently found to be essential for the survival of protozoan and helminth parasites46,50 and 
linked to the anthelmintic drug resistance71.
Similarly, HSP90 is an essential enzyme for some parasites and is believed to act as a sensor in the process of 
transition between different hosts and environments-with dramatic change in temperature, pH and exposure to 
immunological insults-during development, such transition require prompted adaptation72. HSP-90 is an evolu-
tionary conserved chaperon protein essential in all eukaryotes, that is responsible for maintaining organisms in 
homoeostasis and may act as a guard for client proteins against host insults73. Pararosaniline and cetylpyridin-
ium were previously reported to have inhibitory activities against parasite HSP-90s and to interrupt the devel-
opment and growth of protozoan parasites, including Entamoeba histolytica47 and Plasmodium falciparum74. 
Pararosaniline was also years ago subjected to a field study for the anthelmintic activity against schistosomia-
sis75–77. In filarial parasitic nematodes, HSP-90 is an essential enzyme and is the subject of drug screens78–80. Our 
data suggest that both HSP-90 and CYP-450 are potentially good targets for controlling human STNs.
Our interesting finding that the free-living stage of hookworm is a much better predictor of positive drug 
activity against adult hookworms than the free-living C. elegans has potentially interesting implications for evolu-
tion and parasitism. The free-living stages of hookworm larvae and C. elegans have many similarities, living in the 
environment and feeding on bacteria. Therefore, a priori, one might think that free-living larval hookworm stages 
have more in common with the free-living C. elegans than with the adult parasite. We speculate that the envi-
ronmental stages of hookworms and C. elegans are more different than might appear on the surface, as has been 
noted by others in the context of dauer vs L3i development81,82. Hookworm larvae only need to exist as free-living 
worms for a few days before entering the infectious larval stage, awaiting a human host for entry, where it will 
complete its life cycle and reproduce, living for years. Thus, the vast majority of its life (and all of its reproductive 
cycle) is spent in the host. Conversely the entire life and reproductive cycles for C. elegans are spent in the envi-
ronment. Therefore, we speculate that whereas C. elegans has evolved a genome to deal with major environmental 
stresses for its entire lifespan, hookworms, which evolved to parasitize a long time ago83, have evolved so that 
their genomes are primarily adapted to long survival in the host. Consequently, the genes retained by hookworms 
for coping with external environmental threats (such as genes encoding xenobiotic drug transporters) may be at 
least somewhat atrophied by comparison with C. elegans (so that testing anthelmintics on C. elegans gives nega-
tive results that would not be observed in actual hookworms). Along these speculative lines, one might imagine 
that the great expansion of GPCR genes in C. elegans relative to parasites like hookworms84,85 reflects a greater 
need to deal with changing environmental conditions versus a relatively more constant condition in the human 
small intestine, and that the smaller repertoire of GPCRs required for parasitism are thus used by the parasite in 
the short free-living stage as well. These speculations could be tested, for example, by seeing which GPCRs are 
expressed in both developing hookworm larvae and adult hookworms and comparing these to GPCRs expressed 
in C. elegans larvae at similar times as the hookworm larvae. These speculations could also indicate why hook-
worm larvae have a higher number of false positives—developing hookworm larvae might depend on a smaller, 
less redundant set of genes for survival in the environment than C. elegans, which must spend its whole life there.
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Based on our results, we propose a screening pipeline focused on a parasitic nematodes as the main screening 
model (Fig. 6). The decision of choosing between these models could be dependent on the size of a screening 
library. For example, if a screening library is <2,000 compounds, then it might be reasonable to screen directly 
against adult hookworm parasites; however, if the screening library is >10,000 compounds, then hookworm E2L 
will be the most efficient screening model. Hits from such a primary screen will be subjected to data mining, 
cheminformatic analysis, and, possibly, if not known, a mammalian cell toxicity screen, to down select superior 
candidates on the basis of an existing chemotype record, its predicted potential for drug development, the essen-
tiality of the putative target, and safety profile. Compounds that pass these filters will go through a secondary 
screen and validation against hookworm adult parasites (if initially screened against E2L) and/or whipworm adult 
parasites. Compounds with broad spectrum anthelmintic activity could be subjected to further down-selection 
based on data mining/chemoinformatics and dose responses against both adult parasites followed by in vivo tests 
using STN-infected laboratory animals.
Methods
Maintenance of parasites and C. elegans. A. ceylanicum parasites were maintained in golden Syrian 
hamsters following standard protocols86–89. Trichuris muris parasites were maintained in STAT6−/− mice52. C. 
elegans wild type strain N2 Bristol was maintained as per standard protocols90.
Drugs and library. A MicroSource library of 1280 compounds (FDA-approved US drug collection of 1040 
compounds and International drug collection of 240 compounds; Supplemental File 1) was obtained from the Small 
Molecule Screening Facility, University of Massachusetts Medical School Worcester. Screening library was obtained 
in 96-well plate format and a concentration of 1 mM and 20% DMSO. Selected hits from the screening library for 
T. muris in vitro screening were obtained from Milipore Sigma (Sigma Aldrich) and Toronto Research Chemicals.
Adult hookworm in vitro screening. Young adult A. ceylanicum were harvested from the small intestine 
of infected hamsters day 11 post-inoculation (PI) and washed three times using prewarmed medium (RPMI1640, 
100U penicillin, 100 µg/ml streptomycin, 10 µg/ml amphotericin). Three worms were manually picked into each 
well of the 96-well screening plate, containing 97 µl of medium. Using a multichannel pipette 3 µl of 1 mM (20% 
DMSO) drug plates were dispensed into screening plates giving a final concentration of 30 µM (0.75% DMSO). 
In our assays, we left out serum to avoid any possible drug binding and/or metabolism with serum proteins and/
or enzymes. As such, assays have to be scored in a shorter than normal period of time as the health of control 
hookworm adults degenerates more quickly in the absence of serum. Nonetheless, the adults stayed very healthy 
throughout the duration of the assay and the scheme requires that the drugs act quickly (which we viewed as a 
robust positive facet due to potentially limited exposure time of intestinal nematode parasites to drugs as the 
drugs transit through the intestinal tract). Assay plates were incubated for 24 hours at 37 °C and 5% CO2. Drug 
activity was determined using the standard motility index52. Motility index of 3 were given to vigorous worms, 2 
for motile worms, 1 for motile after stimulation by touching and 0 for dead worms. Drug was considered effective 
or a positive, if at least two worms have motility index of ≤1. To validate the results, from two library plates (one 
with a high number of actives and one with a low number of actives) representing ~12% of the total library were 
rescreened on adults. Results from re-screen was identical with the initial screen.
Hookworm developmental screening (E2L). For the egg-to-larva (E2L) hookworm development 
screen, about 120 third-staged infectious larvae (L3i) were orally gavaged into male Syrian hamsters immuno-
suppressed with dexamethasone 1 mg/L in drinking water. Immunosuppressed hamsters can give a significant 
yield of eggs for up to 70 days compared to 12 days in immunocompromised animals. Fecal material was collected 
starting 18 days post infection and about 20 grams of feces were processed for egg isolation and purification 
following salt/sucrose flotation protocol91. Using a multichannel pipette, About 40–60 eggs were dispensed into 
each well of 96-well plate containing E. coli, OP50, as source of food with a final OD600 of 0.3, and a final test 
drug concentration of 10 µM or 30 µM in 0.25% or 0.75% DMSO respectively in 100ul C. elegans S medium92. Test 
plates were incubated at 28 °C for 7 days then scored for development. Test drug was considered hit if >~90% of 
the eggs as judged by eye failed to hatch or hatched but failed to develop into L3i.
Figure 6. Proposed drug screening pipeline based on results shown here. When the screening library is small 
enough (e.g., <2000 compounds) we propose screening directly against adult hookworm parasites to maximize 
quality actives. For larger libraries, we propose screening against hookworm E2L followed by secondary 
screening against adult hookworm parasites. Cheminformatics and data mining can then be employed to 
further downselect. Hookworms adults active compounds will be further prioritized by screening against 
adult whipworms at a single dose and then, if necessary, using a dose response against the adult stages of both 
parasites to select for potent and broad-spectrum actives prior to in vivo testing. Mammalian cell screening can 
be employed at any point to eliminate compounds that may be overly toxic.
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C. elegans E2A screening. Small agar pieces of recently starved plates of C. elegans were “chunked” unto 
Enhanced Nematode Growth (ENG) plates93 spread with E. coli OP50 and incubated at 20 °C for 48 hours. Eggs 
were prepared by bleaching the gravid adults, which were then washed thrice to remove bleach and re-suspended 
in S medium. About 50–60 eggs were dispensed into each well of 96-well plates containing, E. coli-OP50 (OD600 
of 0.3) and a final drug concentration of either 10 µM or 30 µM (0.25% or 0.75% DMSO respectively) and a final 
volume of 100 µL. Plates were wrapped in moist towels to keep hydrated and incubated at 25 °C for 72 hours, at 
which point >90% of controls have developed to early adult stage. Test drug were considered active if >90% of 
the eggs as judged by eye either failed to hatch or hatched but failed to develop into adults.
C. elegans L4-adult screening. Synchronized population of L1 larvae were prepared from bleached eggs 
(see above) after allowing them to hatch overnight in M9 medium94 at room temperature. First-staged larvae (L1s) 
were plated on ENG plates seeded with E. coli-OP50 then incubated at 20 °C for 44 hours until the fourth larval 
(L4) stage. After incubation, L4-worms were washed of the plates using M9 medium and washed trice. About 20 
L4-worms were dispensed into each well of a 96-well plate containing E. coli OP50 (OD600 of 0.3), S medium, and 
30 µM of test drugs, with a final concentration of 0.75% DMSO and final volume of 100 µL. Plates were incubated 
at 25 °C for 96 hours. Drug were considered effective against C. elegans if they killed and/or paralyzed >~80% of 
worms as judged by eye or gave rise to no/very low brood sizes (sterilization of progeny production).
Hookworm L3i and xL3i screening. L3i from standard cultures were washed trice using S medium and 
tested in the drug screen. For screens with exsheathed L3i43, L3i were incubated in saline containing 0.2% sodium 
hypochlorite for about 6 min, until full exsheathment was observed under the light microscope95. Exsheathed L3i 
(xL3i) were incubated in LB medium supplemented with 100 U/ml of Penicillin, 100 µg/ml Streptomycin and 
2.5 µg/ml amphotericin B)43. Half of the library plates (640 drugs) were screened against L3i in S medium and 
xL3i in LB medium (final volume, 100 µL for each). About 50–60 L3i or xL3 were transferred into each well of the 
96-well plate containing 30 µM of test drugs and a final concentration of 0.75% DMSO, and then incubated for 
72 hours at room atmosphere and temperature for L3i or at 37 °C and 10% CO2 for LB induced xL3i. Test drug was 
considered hit if it >~90% as judged by eye of the infective larvae showed no motility.
In silico analysis of screening hits. Cheminformatics on screening hits and analysis of legacy data were 
carried out using Vortex (Dotmatics, Inc.) and the online PubChem database (https://pubchem.ncbi.nlm.nih.
gov/) was used to mine data. The list of hits was assembled via the PubChem database, and the SD structure file 
was downloaded and processed via Vortex. Chemical fingerprints (DotFPCA) were generated and co-clustered 
using the K-means Clustering tool to identify any common chemotypes. The PubChem BioActivity Summary 
tool (no longer supported for multiple-compound input after Nov. 1, 2018) was employed to identify deposited 
PubChem assays that provided dose-dependent cytotoxicity data on the largest number of the anthelmintic can-
didates from the FDA-approved drug library.
Adult whipworm screening. T. muris adult whipworms were harvested from the cecum and small intes-
tines of infected STAT6 −/− mice. Three worms were manually picked into each well of a 24-well plate, 2 wells/ 
test drug and a final volume of 1 ml of medium (as for hookworm adults above). Out of the 39 drugs that hit adult 
hookworms, 32 that were readily available for repurchase were tested against whipworms at final concentrations 
of 100 µM (0.75% DMSO), a dose based on the efficacy of known anthelmintics against T. muris adults in vitro 
and based on previous drug screens36,52,96. Pararosaniline pamoate was unavailable from commercial sources 
instead pararosaniline hydrochloride was purchased and tested against whipworm adults and the following in 
vivo experiments. Test plates were incubated for 48 hours at 37 °C and 5% CO2. Drug activity was assayed using 
the standard motility index as per hookworm adults. Test drug was considered effective against whipworms if at 
least 4 of the 6 tested worms showed motility index of ≤1. DMSO-only controls stayed healthy during the dura-
tion of the test.
Hookworm in vivo study. Four to five-week old male hamsters were infected with ~120 A. ceylanicum L3i. 
On day 17 post inoculation, the number of eggs/gram feces was counted using a modified McMaster technique97. 
Infected animals were grouped accordingly into four similar treatment groups and a placebo control. Animals 
in the treatment groups were orally treated with 400 ul dH2O containing 50 mg/kg of either sulconazole nitrate, 
econazole nitrate, cetylpyridinium chloride or pararosaniline hydrochloride. Two days post treatment, hamsters 
were subjected to an overnight fecal collection. Three days post treatment, animals were euthanized and small 
and large intestines were harvested for worm burden assessment52,89. For the repeat experiment, 100 mg/kg para-
rosaniline was used. Data analysis of intestinal worm burden and fecal egg counts was plotted using Prizm 8 
(GraphPad software Inc, La Jolla, CA, USA). Dots represent the individual worm burdens or fecal egg counts 
for each hamster in each treatment group. In the first in vivo test, SPSS v. 25 Dunnett’s many-to-one comparison 
comparing each treatment to the untreated control. In the second in vivo test with pararosaniline statistical anal-
ysis was done using Prizm 8, one-tailed Mann-Whitney U test.
ethical approval. All animal experiments were carried out under protocols approved by the Institutional 
Animal Care and Use Committee (IACUC) of the University of Massachusetts Medical School (UMMS A-2483 
and UMMS A-2484). Hamsters and mice used in this study were housed, handled, fed and experimentally used 
following the National Institute of Health (NIH) Guide for the Care and Use of Laboratory Animals in Research 
(see 18-F22). Euthanasia was performed by CO2 asphyxiation, followed by bilateral pneumothorax.
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